NVSTEnvista Holdings Corporation
Is the price fair?
Neither cheap nor expensive: nothing decisive, though cheap vs its sector.
Priced for ~4% a year FCF growth. Roughly in line with its three-year revenue growth of 3% a year.
In its normal range: P/E 39.6 vs a 27.6 median over 21 quarters (+44% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Jul 3, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What NVST's price assumes
Envista Holdings Corporation trades at 39.6× earnings against 39.6× for the median Medical Instruments & Supplies name, cheaper than its own group.
Trailing P/E · Medical Instruments & Supplies median 39.6 · cheaper than the typical name in its group
- Price / sales
- 1.52
Price / sales · today's price, trailing year to Jul 3, 2026
- Free cash flow yield
- 5.7%
Free cash flow yield · Medical Instruments & Supplies median 3.4%
- Growth the price implies
- +3.9%
Growth the price implies · The price pays for +3.9% free cash flow growth a year for a decade; the business has delivered +16% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jul 3, 2026
- 1.41
- EV / EBITtoday's price, trailing year to Jul 3, 2026
- 17.0
- EV / salestoday's price, trailing year to Jul 3, 2026
- 1.63
- Healthcare median P/E509 names
- 26.2
- Medical Instruments & Supplies median P/E33 names
- 39.6
- Free cash flow, trailing twelve months
- $248M
- Market capitalisation
- $4.34B
- 3-year revenue growth
- +3.4%
- 3-year free cash flow growth
- +16%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $14.97 |
| Its own P/E history, median | $15.99 |
| Its own P/E history, upper quartile | $32.89 |
| 52-week range | $18.95 – $30.26 |
| Today | $22.99 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #7 of 21 by RyuScore